In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

Now, Novartis hopes to be able to share the data with regulatory authorities in 2025, including the US FDA, in the hope of ...

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's ...

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...

But with cancer remaining as one of the most prevalent and deadly forms of disease worldwide, there are a staggering number ...

Research projects that generative AI could boost the pharma and medical-product industries' annual revenues by up to $110 ...

Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...

This tiered approach allows investors to engage at the level they’re most comfortable with, sparking their interest with a ...

Pfizer's decision could stem from the fairly dismal performance of the only gene therapy for haemophilia A currently on the ...

Those key challenges impacting the care of respiratory diseases include delays in diagnosis due to the intermittent nature of ...

Although Boston, San Francisco, and San Diego are the top three life sciences markets in the US, they are burdened by an oversupply of lab buildings that offer lab space. There is an undersupply of ...